Q-omics provides the consensus-scored SCARNA8 profile across patient tissues and cancer cell-line models. SCARNA8 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SCARNA8 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, SCARNA8 RNA expression shows 14,469 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where SCARNA8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCARNA8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCARNA8 survival associations across molecular data types. SCARNA8 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCARNA8 RNA expression–survival associations across cancer types. High SCARNA8 expression shows unfavorable associations in KIRC, UCEC, MESO, LGG and DLBC, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SCARNA8 RNA expression.
This table summarizes SCARNA8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SCARNA8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCARNA8 shows higher tumor expression in COAD, BLCA, KIRC, HNSC, STAD and LIHC. The COAD box plot shows higher SCARNA8 RNA expression in tumor versus normal tissue (log2 FC = +0.664, t-test p < 0.001).
This table shows molecular features associated with SCARNA8 in patient tissues and cancer cell lines. In patient samples, SCARNA8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
